Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 123 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery MOST POPULAR ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... April 1, 2026 Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... July 13, 2022 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... October 11, 2022 Load more HOT NEWS How To Respond When Your Parents Are Critical Of Your Parenting... FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Whole-Genome Sequencing Could Help Guide AML Treatment
